Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.59 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.59 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL245103 | 1.00 | CHRM2 (0.59) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL247653 | 1.00 | CHRM2 (0.59) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17802359 | 0.88 | CHRM2 (0.50) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17802361 | 0.88 | CHRM2 (0.50) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17802339 | 0.88 | CHRM1 (0.50) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17814911 | 0.88 | CHRM2 (0.50) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17802337 | 0.88 | CHRM1 (0.50) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL244385 | 0.82 | — | — | |
| SCHEMBL3397822 | 0.82 | — | — | |
| SCHEMBL242417 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016088138-A1 | DIPHENYLOXIRANES, PROCESS FOR PREPARATION THEREOF, AND ITS USE IN AN ENANTIOSELECTIVE SYNTHESIS OF (+)-SERTRALINE | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-06-09 | — | — | WO | claimed |
| US-11453677-B2 | Tricyclic compounds useful to treat orthomyxovirus infections | NOVARTIS AG (CH) | 2022-09-27 | — | — | US | disclosed |
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-30 | — | — | US | disclosed |
| US-20210186969-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | Janssen Biopharma, Inc. (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3426656-B1 | TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2021-05-12 | — | — | EP | disclosed |
| US-10980805-B2 | Aza-pyridone compounds and uses thereof | Janssen Biopharma, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10858366-B2 | Tricyclic compounds useful to treat orthomyxovirus infections | NOVARTIS AG (CH) | 2020-12-08 | — | — | US | disclosed |
| US-20200347072-A1 | Tricyclic Compounds Useful to Treat Orthomyxovirus Infections | NOVARTIS AG (CH) | 2020-11-05 | — | — | US | disclosed |
| EP-3030566-B1 | 7,8-DIHYDRO-3H-PYRAZINO[1,2-B]PYRIDAZINE-3,5(6H)-DIONE COMPOUNDS AND USES THEREOF | JANSSEN BIOPHARMA INC (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10702523-B2 | AZA-pyridone compounds and uses thereof | Janssen Biopharma, Inc. (US) | 2020-07-07 | — | — | US | disclosed |
| WO-2002000631-A2 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |
| EP-1154764-A1 | EPOXIDE HYDROLASE COMPLEXES AND METHODS THEREWITH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000048593-A1 | EPOXIDE HYDROLASE COMPLEXES AND METHODS THEREWITH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-08-24 | — | — | WO | disclosed |
| EP-0794230-B1 | Curable composition based on silyl-functionalized polyethers and epoxy resins | KANEKA CORP (JP) | 1999-11-10 | — | — | EP | disclosed |
| US-5889124-A | CONSISTS OF AN OXYALKYLENE POLYMER WITH ATLEAST ONE SILICON CONTAINING GROUP HAVING ATLEAST ONE HYDROXYL OR HYDROLYZABLE GROUP BONDED TO A SILICON ATOM, AN EPOXY RESIN, A KETIMINE COMPOUND AND AN ALDEHYDE OR KETONE COMPOUND | KANEKA CORPORATION (JP) | 1999-03-30 | — | — | US | disclosed |
| CN-1201919-A | Production process of colored fine particulate composition and colored fine particulate composition produced by process | DAINICHISEIKA COLOR CHEM (JP) | 1998-12-16 | — | — | CN | disclosed |
| EP-0794230-A2 | Curable composition based on silyl-functionalized polyethers and epoxy resins | Kaneka Corporation (JP) | 1997-09-10 | — | — | EP | disclosed |
| CN-1107586-A | Toner and developer for developing electrostatic image, process for production thereof and image forming method | CANON KK (JP) | 1995-08-30 | — | — | CN | disclosed |
| US-4113972-A | ANTIDEPRESSANTS | BEECHAM GROUP LIMITED (GB) | 1978-09-12 | — | — | US | disclosed |
| US-4101676-A | Diphenylpropylamines to treat depression | BEECHAM GROUP LIMITED (GB) | 1978-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858366-B2 | Tricyclic compounds useful to treat orthomyxovirus infections | ZC3HAV1, OTC, THOP1 | CHRM2 2939/4885CHRM4 2172/4885CHRM5 2630/4885 |
| US-10980805-B2 | Aza-pyridone compounds and uses thereof | PNPO, ITPA, PDXK | CHRM2 359/4885CHRM4 109/4885CHRM5 266/4885 |
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | FAAH, EPHX1, FAAH2 | CHRM2 508/4885CHRM4 306/4885CHRM5 288/4885 |
| US-20210186969-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | PNPO, ITPA, PDXK | CHRM2 359/4885CHRM4 109/4885CHRM5 266/4885 |
| US-20200347072-A1 | Tricyclic Compounds Useful to Treat Orthomyxovirus Infections | ZC3HAV1, OTC, THOP1 | CHRM2 2596/4885CHRM4 1810/4885CHRM5 2284/4885 |
| US-10702523-B2 | AZA-pyridone compounds and uses thereof | PNPO, ITPA, PDXK | CHRM2 359/4885CHRM4 109/4885CHRM5 266/4885 |
| US-11453677-B2 | Tricyclic compounds useful to treat orthomyxovirus infections | ZC3HAV1, OTC, THOP1 | CHRM2 2596/4885CHRM4 1810/4885CHRM5 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.